Search results
Showing 586 to 600 of 1112 results for criteria
NICE has developed a Medtech Innovation Briefing (MIB) on the Space GlucoseControl system for managing blood-glucose in critically ill patients in intensive care
NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.
invasive testing and increase resource use by the health service. Referral criteria that are too narrow will delay the emergency...
as the 'gold standard' for cases of uncertainty and to standardise the criteria, expertise and procedures for radiological assessment....
NICE has developed a Medtech Innovation Briefing (MIB) on the OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.
This guideline covers interventions and support for children, young people and adults with a learning disability and behaviour that challenges. It highlights the importance of understanding the cause of behaviour that challenges, and performing thorough assessments so that steps can be taken to help people change their behaviour and improve their quality of life. The guideline also covers support and intervention for family members or carers.
This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process
This guideline covers the planning, delivery and review of social work interventions for adults who have complex needs. It promotes ways for social work professionals, other care staff and people with complex needs to work together to make decisions about care and support.
Infliximab for treating moderate to severe plaque psoriasis (TA134)
Evidence-based recommendations on infliximab for treating moderate to severe psoriasis in adults.
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)
Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.
Evidence-based recommendations on olipudase alfa (Xenpozyme) for treating acid sphingomyelinase deficiency (Niemann–Pick disease) in people with type AB or type B.
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.